| Identification | Back Directory | [Name]
L-Valinamide, 3-amino-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-buten-1-yl]-N,3-dimethyl- | [CAS]
1977557-86-0 | [Synonyms]
Hemiasterlin (SC209)
L-Valinamide, 3-amino-N,β,β-trimethyl-L-phenylalanyl-N-[(1S,2E)-3-carboxy-1-(1-methylethyl)-2-buten-1-yl]-N,3-dimethyl- | [Molecular Formula]
C27H44N4O4 | [MOL File]
1977557-86-0.mol | [Molecular Weight]
488.66 |
| Chemical Properties | Back Directory | [Boiling point ]
705.0±60.0 °C(Predicted) | [density ]
1.091±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
4.68±0.19(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
SC209, an ADC cytotoxin extracted from patent WO2021247798, is used in synthesis of anti-EGFR antibody-drug conjugate ADC. SC209 is the payload of STRO-002[1][2]. | [References]
[1] Alice Yam, et al. Bispecific antibody-drug conjugates targeting egfr and muc1 and uses thereof. Patent. WO2021247798.
[2] De Almeida V, et al. Preclinical activity and safety of STRO-002, a novel ADC targeting folate receptor alpha for ovarian cancer. Gynecologic Oncology, 2018, 149: 50. |
|
|